Chilean technology company Innocon has made significant progress in the development of oral vaccines for salmon farming, with a special focus on the prevention of Salmonic Rickettsial Septicemia (SRS).
SRS is a bacterial disease that represents a significant challenge for the salmon industry. Addressing the disease effectively is crucial for the long-term continuity of the aquaculture industry in a sustainable manner.
“Our current project focuses on an oral vaccine against SRS, but we are also designing this technology so it can serve as a vehicle to prevent other diseases in the future. This wide vision seeks to address multiple health challenges in an efficient and sustainable manner,” said Milica Sevo, head of R&D Microbiology at Innocon.
The vaccine is currently in the validation stage to prevent SRS and other diseases. “The tests carried out in recent months corroborate the potential of the technology in salmon farming, which will help not only the industry itself but also the preservation of the aquatic ecosystem and the promotion of sustainable farming,” concluded Jorge Sepúlveda, head of R&D Molecular Biology of the company.